1 / 45

Diagnosis, Prognosis, and Management of aHUS

Diagnosis, Prognosis, and Management of aHUS. Program Goals. TMA Disorders Are Now Classified by Molecular Mechanism. Hereditary Disorders Resulting in TMA. Acquired Causes of TMA. Complex Mechanisms May Contribute to Acquired TMA. Effects of Uncontrolled or Excessive Complement Activation.

emmanuel-hale
Télécharger la présentation

Diagnosis, Prognosis, and Management of aHUS

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Diagnosis, Prognosis, and Management of aHUS

  2. Program Goals

  3. TMA Disorders Are Now Classified by Molecular Mechanism

  4. Hereditary Disorders Resulting in TMA

  5. Acquired Causes of TMA

  6. Complex Mechanisms May Contribute to Acquired TMA

  7. Effects of Uncontrolled or Excessive Complement Activation

  8. Complement-Mediated TMA (aHUS) Can Affect Multiple Organs, Tissues

  9. Extrarenal Manifestations Are Common in aHUS

  10. Keys to Diagnosing aHUS

  11. No Role for Complement-Level Testing in the Diagnosis of aHUS

  12. Challenges in Diagnosing aHUS

  13. Complement-Amplifying Conditions May Unmask aHUS

  14. Complement-Amplifying Conditions Commonly Unmask aHUS

  15. aHUS and Complement-Amplifying Events

  16. Unmasking the Diagnosis of Complement-Mediated TMA

  17. Management Options for aHUS Have Been Limited

  18. Challenges in Evaluating PI/PE Therapy

  19. Response to Plasma Therapy for aHUS

  20. Plasma Therapy for aHUS Is Clinically Inadequate

  21. Recommendations of French Study Group for Defining PE/PI Failure

  22. Potential for Significant Morbidity/Mortality Regardless of Overt Laboratory or Clinical Signs

  23. Eculizumab: Humanized First-in-Class Anti-C5 Antibody

  24. Eculizimab Dosing Schedule: Adults

  25. Eculizumab Multinational Clinical Program Includes Broad aHUS Patient Population

  26. Eculizumab Multinational, Multicenter Clinical Program of Prospective Trials in aHUS (N = 100)

  27. Improvement in Hematologic Markers of Complement-mediated TMA Across All Studies at 26 weeks

  28. Rapid and Sustained Improvement in Hematologic Markers of Complement-mediated TMA With or Without Identified Genetic Mutation

  29. Early Eculizumab Therapy Associated With High Likelihood of Eliminating Dialysis

  30. Prospective Trial of Eculizumab in Adults With aHUS

  31. Safety Profile of Eculizumab in Prospective Trial of Adults With aHUS

  32. Eculizumab and Serious Meningococcal Infections

  33. Key Benefits of Eculizumab

  34. Abbreviations

  35. Abbreviations (cont)

  36. Abbreviations (cont)

  37. References

  38. References (cont)

  39. References (cont)

  40. References (cont)

  41. References (cont)

  42. References (cont)

  43. References (cont)

  44. References (cont)

  45. References (cont)

More Related